Plain-English translation of NCT07614230 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing dapagliflozin, a diabetes medication, to see if it can slow down the buildup of plaque in the arteries of your heart. You'll be randomly assigned to either take the medication daily or receive standard diabetes care without it. The study will use specialized heart imaging to measure whether the medication helps protect your arteries over 18 months.
People with type 2 diabetes are at high risk for heart disease, and the buildup of plaque in heart arteries can be life-threatening. Researchers want to know if this medication can protect your heart arteries better than standard care alone.
You likely qualify if…
You likely don't qualify if…
If you join, you'll start by having a specialized CT scan of your heart arteries and blood tests to establish a baseline. You'll then be randomly assigned to either take the medication once daily or continue standard care. Over 18 months, you'll have follow-up visits at 6, 12, and 18 months to check how you're doing, report any side effects, and have repeat imaging and blood tests at the end to see whether the medication has helped slow plaque buildup.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
China